Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Signs Up Seven New York Institutions To Create Biomedical Discovery Engine

Executive Summary

Pfizer doesn't exactly do things by halves. Two years after pulling off the sector's biggest merger, it now appears to be carrying out the largest-scale – and most ambitious – academic tie-up yet.
Advertisement

Related Content

Mount Sinai Taps Smith For New Effort In Entrepreneurship
Pfizer Teams With Eight Boston-Area Research Institutions In $100MM Tie-Up
Empire State Of Mind: Lilly Aims To Build Academic Ties With N.Y. Research Center
Empire State Of Mind: Lilly Aims To Build Academic Ties With N.Y. Research Center
Deals Of The Week: Novartis/Genoptix, Amgen/BioVex, Ligand/Cydex
As Pfizer And UCSF Tighten Ties, More Deals With Academia Could Follow
As Pfizer And UCSF Tighten Ties, More Deals With Academia Could Follow
Pharma and Academia: Finding New Ways to Join Hands for Mutual Benefit
GSK Tries to Mimic Real-World Biotech
GSK Tries to Mimic Real-World Biotech

Topics

Advertisement
UsernamePublicRestriction

Register

PS053081

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel